102 results about "Membrane binding" patented technology

The present invention relates to a biosensor which comprises an electrode system including at least one pair of electrodes, at least one insulating base plate for supporting the electrode system, a first reaction layer provided at least on a working electrode of the electrode system, including an organic compound having a functional group capable of bonding or being adsorbed to an electrode and a hydrophobic hydrocarbon group, a second reaction layer provided on the first reaction layer, including an amphiphilic lipid capable of bonding or being adsorbed to a hydrophobic portion of the first reaction layer, and a reagent system carried in a two-component membrane composed of the first and second reaction layers, including at least membrane-binding type pyrroquinoline quinone-dependent glucose dehydrogenase and an electron mediator.

The invention provides vitamin K-dependent polypeptides with enhanced membrane binding affinity. These polypeptides can be used to modulate clot formation in mammals. Methods of modulating clot formation in mammals are also described.

Detection and characterization of molecular interactions on membrane surfaces is important to biological and pharmacological research. In one embodiment, silver nanocubes interfaced with glass-supported model membranes form a label-free sensor that measures protein binding to the membrane. The present device and technique utilizes plasmon resonance scattering of nanoparticles, which are chemically coupled to the membrane. In contrast to other plasmonic sensing techniques, this method features simple, solution-based device fabrication and readout. Static and dynamic protein/membrane binding are monitored and quantified.

A cross-protective influenza virus vaccine has been designed based on the incorporation of the genetically engineered, highly conserved M2 influenza viral protein optionally in combination with an adjuvant such as a bacterial flagellin protein incorporated into the membrane of a virosome or virus-like particles. Immunogenicity and the breadth of cross protection efficacy are significantly enhanced using multiple copies of the influenza M2 protein as a membrane bound tetramer and/or in combination with a membrane bound adjuvant. A method for vaccinating a subject for influenza A has also been developed that results in broad and improved cross-protection against multiple subtypes of influenza A virus.

An environmentally sensitive membrane binding polypeptide, pH (low)-sensitive membrane peptide (pHLIP) has improved insertion kinetics balanced with solubility to selectively target acidic tissues.

A protein obtainable from a non pathogenic microorganism, said protein having mucosa binding promoting activity and a molecular weight of 20-40 kD is disclosed. Application of such a protein or a peptide derived therefrom in a method of screening non pathogenic microorganisms for a microorganism capable of specifically binding mucosa, said method comprising detection in a manner known per se of the presence of a particular protein on or in a microorganism or in a culture of microorganisms, said particular protein being the already defined protein. Kits suitable for such a screening method are also disclosed. Use of a component selected from the group of components comprising a protein or peptide as defined an expression vector comprising nucleic acid encoding such protein or peptide a recombinant microorganism or a part of said microorganism expressing such protein or peptide, said part expressing mucosa binding promoting activity a non pathogenic microorganism capable of expressing such protein or peptide or a part of said microorganism, said part expressing mucosa binding promoting activity as pharmaceutically active component in a pharmaceutical composition for prophylaxis and/or treatment of disease or illness associated with a mucosa colonising pathogenic microorganism. Use of such components as food additive and compositions comprising such components are described.

The invention provides vitamin K-dependent polypeptides with enhanced membrane binding affinity. These polypeptides can be used to modulate clot formation in mammals. Methods of modulating clot formation in mammals are also described.

The invention discloses a human feces DNA extraction method. The prior art is complicated and time-consuming; and the trace DNAs extracted by the previous sampling method is too little to perform molecular diagnosis. The extraction method uses selective sample collection PSC equipment for feces samples and adopts a low temperature preservation method. The extraction method comprises the following steps: picking a sample by using a sterilized gun head or sterilized blade and directly placing the picked sample on ice; and adding a feces lysis solution, fully cracking and evenly mixing, adding bovine serum albumin, centrifuging to remove the supernatant, adding protease K to perform a digestion reaction at 58 DEG C, then adding a protein precipitation solution to precipitate the protein, centrifuging to obtain the supernatant, adding a silica gel membrane binding solution to fully bind DNAs, centrifuging to obtain precipitates, adding a silica gel membrane washing solution to wash twice, centrifuging, and adding a TE (Tris + EDTA) buffer solution to finally obtain a preservation solution with DNAs. The human feces DNA extraction method has the advantages of high repeatability and stability, simpleness and short time.

The present invention relates to membrane binding diastereomeric peptides comprising amino acid sequences corresponding to a fragment of a transmembrane proteins, wherein at least two amino acid residues of the diastereomeric peptides being in a D-isomer configuration. The diastereomeric peptides are useful in inhibiting fusion membrane protein events, including specifically viral replication and transmission.

The invention provides vitamin k-dependent polypeptides with enhanced membrane binding affinity. These polypeptides can be used to modulate clot formation in mammals. Methods of modulating clot formation in mammals are also described.

Recombinant microbial cells are disclosed herein that produce an oil comprising at least 28 percent eicosapentaenoic acid (EPA) measured as a weight percent of dry cell weight. These cells may comprise a polynucleotide sequence encoding an active acyl-CoA:lysophosphatidylcholine acyltransferase (LPCAT) comprising at least one amino acid mutation in a membrane-bound O-acyltransferase motif. In addition, the cells may comprise a down-regulation of an endogenous polynucleotide sequence encoding Sou2 sorbitol utilization protein, and/or one or more polynucleotides encoding phospholipid:diacylglycerol acyltransferase (PDAT), delta-12 desaturase, a dihomo-gamma-linolenic acid (DGLA) synthase multizyme, delta-8 desaturase, malonyl-CoA synthetase (MCS), or acyl-CoA:lysophosphatidic acid acyltransferase (LPAAT). Also disclosed are methods of using the recombinant microbial cells to produce oil containing omega-3 polyunsaturated fatty acids such as EPA.

A delivery system for introducing a cargo molecule into cytosol of a living cell can include: a first membrane binding element linked to an endosomal compartment disrupting element through a first linker having one or more anionic moieties; and a second membrane binding element linked to an exogenous cargo molecule through a second linker having one or more anionic moieties, the second linker having a region that is selectively cleavable, wherein the first and second membrane binding elements both induce endocytosis into an early/recycling endosome and the endosomal compartment disrupting element destabilizes the early/recycling endosome such that the exogenous cargo molecule is released from the second membrane binding element and into the cytosol of the living cell.

The present invention provides nucleic acid molecules encoding annexin 1 (ANX1) and annexin 4 (ANX4) that belong to a multigene family of calcium-dependent membrane binding proteins. ANX1 and ANX4 are inducible by abscisic acid (ABA), salt and other various stress treatments. The anx1 and anx4 mutant plants are characterized by their hypersensitivity to salt and ABA during seed germination and early seedling growth. The invention can be utilized to generate transgenic plants that are tolerant to environmental stress.

The reagent card for quantitatively detecting the helicobacter pylori antibody by fluorescence chromatography comprises a card shell and a test strip arranged in the card shell, wherein the test stripcomprises a bottom plate, and a nitrocellulose membrane, a conjugate pad and a sample pad which are adhered to the bottom plate; the sample pad, the conjugate pad and the nitrocellulose membrane aresequentially overlapped end to end for a preset length; the nitrocellulose membrane is coated with a helicobacter pylori natural antigen through lineation; and lanthanide-labeled latex microspheres coated with helicobacter pylori recombinant protein antigens are sprayed on the conjugate pad. The reagent card provided by the invention is a helicobacter pylori antibody lanthanide time-resolved fluorescence chromatography quantitative detection reagent card prepared by adopting a helicobacter pylori recombinant protein antigen and natural antigen combined double-antigen sandwich method, and can realize rapid quantitative detection of a helicobacter pylori antibody (IgG antibody). Correspondingly, the invention further provides a detection method for quantitatively detecting the helicobacter pylori antibody through fluorescence chromatography.

The invention relates to the technical field of brewing of Baijiu, and in particular to extraction of microbial genome DNA in fermented grains. The method comprises the following steps: (1) wall breaking of microbial cells in the fermented grains: weighing a fermented grain sample and quartz sand, adding lysate, and conducting shaking centrifugation so as to obtain a coarse nucleic acid extracting solution; and (2) nucleic acid purification: adding a mixture of phenol: chloroform: isoamylol (P.C.I), conducting centrifugation to remove protein, adding a silica gel membrane binding solution, conducting filtering by virtue of a nucleic acid purification column, eluting the nucleic acid purification column by virtue of 70% ethanol, adding de-ionized water or a TE solution and preserving the DNA. The method is simple and convenient to operate, low in cost consumption, low in labor intensity and time-saving, and the extracted microbial genome in the fermented grains is high in quality and is applicable to such molecular biology analysis as next generation sequencing, fluorescent quantitative PCR and the like.

The invention discloses an application of a targeted complement inhibitor in preparation of drugs for improving brain death donor livers. The application of the targeted complement inhibitor in preparation of the drugs for improving the brain death donor livers is characterized in that a complement receptor 2 (CR2) is utilized to connect a membrane binding regulatory factor Crry; with targeted binding of the CR2 to complement activation and local injury, the membrane-binding regulatory factor utilized to regulate different stages of complement cascade, and a mouse brain death model established, the changes of the liver functions between a CR2-Cryy treatment group and a control group are compared; results indicate that the targeted complement inhibitor CR2-Crry is effective in improving donor liver injury after brain death and can reduce liver inflammatory response, oxidative stress damage and hepatocyte apoptosis. The role of this complement inhibitor in improving donor liver functionafter brain death is further confirmed by complement knockout mice.

Method for the recombinant expression of mammalian cell membrane-bound human CCN1 or a CCN1 domain thereof in mammalian cells, characterized in transforming a mammalian host cell with a vector encoding CCN1 or a CCN1 domain thereof C-terminally fused to a mammalian cell transmembrane domain (CCN1 fusion protein), expressing said CCN1 or CCN1 domain fusion protein in said host cell and recovering said membrane bound CCN1 or said CCN1 domain thereof. And use of such membrane bound CCN1 and domain for the generation of antibodies. An antibody against human CCN1 is useful for the treatment of diseases.

Expression system of peptides on the bacterial surface characterised in that membrane-binding region the conserved sequence of the MSP1a protein of Anaplasma marginale.